文献速递类风湿关节炎

甲氨蝶呤联合低剂量泼尼松通过降低早期类风湿关节炎患者单核细胞RANK表达下调破骨细胞功能

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis.
PubMed 文献 · RMD Open · 2017-07-13

该研究比较了早期类风湿关节炎患者甲氨蝶呤联合低剂量泼尼松治疗前后与健康供者的循环破骨细胞前体及破骨细胞分化。结果显示治疗前单核细胞经典活化标志物和RANK表达升高、血清sRANKL升高,治疗后均降至健康对照水平,破骨细胞数量无差异但吸收面积百分比和每陷窝吸收面积减少。结论提示MTX+PDN通过降低单核细胞RANK表面表达下调破骨细胞功能。

要点

  • 早期RA患者基线单核细胞活化标志物和RANK表达升高,MTX+PDN治疗后降至健康对照水平。
  • 治疗前血清sRANKL升高,治疗后正常化。
  • 破骨细胞数量各组无差异,但治疗后吸收面积百分比和每陷窝吸收面积减少。

核心结论

  • MTX联合低剂量PDN通过降低单核细胞RANK表面表达下调破骨细胞功能。

研究设计与样本

  • 研究纳入RA患者,在MTX治疗前及至少6个月后进行分析,并与健康供者比较。
  • 检测循环白细胞RANK配体表面表达、单核细胞亚群频率与表型、血清骨转换标志物和细胞因子,并进行破骨细胞分化实验。

主要发现

  • 与健康对照相比,RA患者基线单核细胞经典活化标志物和RANK升高,MTX+PDN暴露后降至对照水平。
  • 各组破骨细胞数量无差异,但治疗后吸收面积百分比和每陷窝吸收面积减少。
  • 血清可溶性RANKL水平基线高于健康供者,治疗后正常化。

临床怎么用

  • 早期RA启动MTX联合低剂量PDN治疗可降低单核细胞RANK表达并抑制破骨细胞吸收功能,支持其减缓骨破坏的作用机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is a systemic, immune-mediated inflammatory disease that ultimately leads to bone erosions and joint destruction. Methotrexate (MTX) slows bone damage but the mechanism by which it acts is still unknown. In this study, we aimed to assess the effect of MTX and low-dose prednisolone (PDN) on circulating osteoclast (OC) precursors and OC differentiation in patients with RA. METHODS: Patients with RA before and at least 6 months after MTX therapy were analysed and compared with healthy donors. A blood sample was collected in order to assess receptor activator of NF-κβ (RANK) ligand surface expression on circulating leucocytes and frequency and phenotype of monocyte subpopulations. Quantification of serum levels of bone turnover markers and cytokines and OC differentiation assays were performed. RESULTS: Classical activation markers of monocytes and RANK increased in patients with RA at baseline, compared with control healthy donors, and after MTX and low-dose PDN (MTX+PDN) exposure they decreased to control levels. Although the number of OC was not different between groups, the percentage of resorbed area and the resorbed area per pit reduced after treatment. Serum soluble receptor activator of nuclear factor-kappa (RANKL) levels increased at baseline compared with healthy donors and normalised after therapy. CONCLUSION: Our results suggest that MTX+PDN play an important role in downregulating OC function, which we believe occurs through the decrease in RANK surface expression in monocytes.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Perpétuo IP, Caetano-Lopes J, Rodrigues AM, et al. Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis. RMD Open. 2017. PMID: 28955481. doi:10.1136/rmdopen-2016-000365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。